Congress Gives the FDA Funds to Oversee Hemp CBD

December 23, 2019 09:00:54

For the past few years, cannabidiol (CBD) has held the medical, health and wellness and sports communities enthralled. If you’ve been paying any attention to the news, chances are you’ve heard of it too. The compound was barely known three years ago, but now it’s gracing the top of search lists and experts claim the hemp/CBD market will be worth billions by 2026.

Cannabidiol’s main draw lies in its medicinal properties. It is a potent and versatile medicine, with users claiming it gave them relief from a variety of medical conditions including high blood pressure, anxiety, and depression. Last year, the U.S. Food and Drug Administration approved Epidiolex, a CBD-based drug to treat…

Read More >>

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.